HIV-1 gp41 Antibody (5A1): sc-57813
- HIV-1 gp41 Antibody (5A1) is a mouse monoclonal IgG1 provided at 100 µg/ml
- raised against recombinant antigen corresponding to Strain IIIB amino acids 466-753 of HIV-1 gp41
- recommended for detection of gp41 envelope glycoprotein of HIV-1 origin by WB
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for HIV-1 gp41 Antibody (5A1). This work is in progress.
QUICK LINKS
SEE ALSO...
HIV-1 gp41 Antibody (5A1) is a mouse monoclonal IgG1 antibody that detects HIV-1 gp41 specifically in HIV-1 by western blotting (WB). HIV-1 gp41 is a critical glyco-envelope protein that plays a vital role in the life cycle of the HIV-1 virus, facilitating the fusion of the viral envelope with the host cell membrane, which is essential for viral entry into target cells. This process is crucial because anti-HIV-1 gp41 antibody (5A1) allows the virus to infect key immune cells, such as helper T cells, thereby undermining the host′s immune response and contributing to the progression of acquired immune deficiency syndrome (AIDS). The structure of gp41 is particularly important as gp41 contains a hydrophobic fusion peptide that anchors the protein to the host cell membrane, and conformational changes during the fusion process are key to the virus′s ability to infect cells. Understanding the function and structure of gp41 not only aids in the development of therapeutic strategies but also enhances the design of vaccines aimed at eliciting an immune response against this critical viral component. HIV-1 gp41 monoclonal antibody (5A1) is an invaluable tool for researchers studying HIV-1 pathogenesis and the immune response to viral infections.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
HIV-1 gp41 Antibody (5A1) References:
- Progress towards the development of a HIV-1 gp41-directed vaccine. | McGaughey, GB., et al. 2004. Curr HIV Res. 2: 193-204. PMID: 15078183
- HIV-1 gp41 as a target for viral entry inhibition. | Root, MJ. and Steger, HK. 2004. Curr Pharm Des. 10: 1805-25. PMID: 15180542
- Targeting HIV-1 gp41 in close proximity to the membrane using antibody and other molecules. | Gach, JS., et al. 2011. Curr Top Med Chem. 11: 2997-3021. PMID: 22044228
- The HIV-1 gp41 ectodomain is cleaved by matriptase to produce a chemotactic peptide that acts through FPR2. | Wood, MP., et al. 2014. Immunology. 142: 474-83. PMID: 24617769
- HIV-1 gp41 transmembrane oligomerization monitored by FRET and FCS. | Schroeder, S., et al. 2018. FEBS Lett. 592: 939-948. PMID: 29453892
- Trilobatin as an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope. | Yin, S., et al. 2018. FEBS Lett. 592: 2361-2377. PMID: 29802645
- Prediction and validation of HIV-1 gp41 ecto-transmembrane domain post-fusion trimeric structure using molecular modeling. | Gorai, B., et al. 2020. J Biomol Struct Dyn. 38: 2592-2603. PMID: 31232193
- Structure of HIV-1 gp41 with its membrane anchors targeted by neutralizing antibodies. | Caillat, C., et al. 2021. Elife. 10: PMID: 33871352
- Conformational plasticity of the HIV-1 gp41 immunodominant region is recognized by multiple non-neutralizing antibodies. | Cook, JD., et al. 2022. Commun Biol. 5: 291. PMID: 35361878
- A HIV-1 Gp41 Peptide-Liposome Vaccine Elicits Neutralizing Epitope-Targeted Antibody Responses in Healthy Individuals. | Erdmann, NB., et al. 2024. medRxiv.. PMID: 38562833
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HIV-1 gp41 Antibody (5A1) | sc-57813 | 100 µg/ml | $322.00 |